Stockscreener 앱 받기
18.44
4.80%
-0.93
시간 외 거래:
18.44
전일 마감가:
$19.37
열려 있는:
$19.02
하루 거래량:
1.93M
Relative Volume:
1.56
시가총액:
$1.09B
수익:
-
순이익/손실:
$-883.08M
주가수익비율:
-0.0553
EPS:
-333.4782
순현금흐름:
$-150.65M
1주 성능:
-15.76%
1개월 성능:
-18.80%
6개월 성능:
+51.77%
1년 성능:
-46.84%
1일 변동 폭
$17.55
$19.37
1주일 범위
$17.55
$23.82
52주 변동 폭
$6.50
$49.95
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
18.44 | 1.15B | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Jefferies | Buy |
| 2026-03-19 | 개시 | Wells Fargo | Overweight |
| 2026-01-09 | 개시 | Citigroup | Buy |
| 2025-12-17 | 개시 | TD Cowen | Buy |
| 2025-12-09 | 개시 | JP Morgan | Overweight |
| 2025-11-25 | 재개 | Wedbush | Neutral |
| 2025-10-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | 업그레이드 | Stifel | Hold → Buy |
| 2025-06-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
Vor Biopharma at Stifel 2026 forum: telitacicept pushes dual path By Investing.com - Investing.com Canada
Vor Biopharma Inc.(NasdaqGS: VOR) added to S&P Global BMI Index - marketscreener.com
Vor Biopharma advances global trials for telita... - Pluang
Vor Biopharma: A Funded Replication Story With Franchise Potential (NASDAQ:VOR) - Seeking Alpha
Is Phase 3 Enrollment Complete Altering The Investment Case For Vor Biopharma (VOR)? - simplywall.st
Jefferies Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $48 - moomoo.com
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com India
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
Vor Biopharma Inc. (VOR) Latest Press Releases & Corporate News - Yahoo Finance
VOR: Phase III MG trial enrollment complete; robust efficacy and market expansion plans underway - TradingView
Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Mar - GuruFocus
Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis - marketscreener.com
Vor Biopharma (VOR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VOR - MarketBeat
Vor Biopharma Stock Price Forecast. Should You Buy VOR? - StockInvest.us
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Vor Bio To Participate in Upcoming September Conferences - marketscreener.com
Vor Biopharma Inc. (VOR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vor Biopharma (VOR) RA Capital-linked option yields 1,500 shares - Stock Titan
Vor (VOR) Quarterly Results: EPS Does Not Reach the Reported Estimate in the Latest Reading; Price Reaction: Shares Fall 2.78% in the Latest SessionDebt Analysis Report - dars.gov.et
Why Did Vor Biopharma (VOR) Stock Drop After Its Latest Update? - Sahm
Vor (VOR) Snapshot: Adds 1.28% to Close at $23.36 on the Day; Key Range: Support at $22.19 and Resistance at $24.53 Frame the Range in the Latest ReadingHot Stock Picks - vinanet.vn
US and Canadian markets settled this week on a negative note, Two stocks to consider – LITH, VOR - kalkine.ca
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake - Stock Titan
Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership - Stock Titan
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright - MarketBeat
VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920 - TradingKey
Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock - Stock Titan
Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18 - webull.com
VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00 - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings - MarketBeat
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma (VOR) Reports Improved Cash Position and Reduced L - GuruFocus
Vor Biopharma Reports Q2 2026 Financial Results in SEC Form 10-Q Filing - Kalkine Media
Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate - scanx.trade
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results - MarketBeat
Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations - GuruFocus
VOR Stock Update: Telitacicept Advances Amid Mixed Financial Sig - GuruFocus
Vor Biopharma Shares Drop After Q2 Results - marketscreener.com
Vor Biopharma Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs - TradingView
Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Vor Biopharma Inc. 2Q 2026: Net loss $(62.8M), EPS $(1.16) — 10-Q Summary - TradingView
Vor Biopharma (VOR) cuts losses as telitacicept trials advance and cash runway reaches 2029 - Stock Titan
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR - MarketBeat
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):